SCHEMBL10059435

SCHEMBL10059435

FC(F)c1ncccc1Br

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 1/20 0.36
AXL P30530 1/20 0.35
MAPT P10636 4/20 0.33
KDM4E B2RXH2 4/20 0.33
SMN1; SMN2 Q16637 3/20 0.33
HTT P42858 3/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
TP53 P04637 2/20 0.33
HSP90AA1 P07900 2/20 0.33
TDP1 Q9NUW8 2/20 0.33
APAF1 O14727 1/20 0.33
TDP2 O95551 1/20 0.33
ALDH1A1 P00352 1/20 0.33
CASP3 P42574 1/20 0.33
SENP8 Q96LD8 1/20 0.33
SENP7 Q9BQF6 1/20 0.33
SENP6 Q9GZR1 1/20 0.33
TRIM24 O15164 1/20 0.33
TRIM33 Q9UPN9 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25275809 0.84 DPP4 (0.36) TRPM8
SCHEMBL2627815 0.79 TRPM8 (0.40) TRPM8AXLMAPTKDM4ESMN1; SMN2
SCHEMBL31068984 0.79 TRPM8 (0.40) TRPM8AXLMAPTKDM4ESMN1; SMN2
SCHEMBL14333289 0.79 AXL (0.41) TRPM8AXLMAPTKDM4ESMN1; SMN2
SCHEMBL22922224 0.74 TGFBR1 (0.38) TRPM8MAPTKDM4ESMN1; SMN2HTT
SCHEMBL30674901 0.74 TRPM8 (0.40) TRPM8AXLMAPTKDM4ESMN1; SMN2
SCHEMBL23295658 0.74 TRPM8 (0.40) TRPM8AXLMAPTKDM4ESMN1; SMN2
SCHEMBL29808658 0.74 TRPM8 (0.40) TRPM8AXLMAPTKDM4ESMN1; SMN2
SCHEMBL23006312 0.74 TRPM8 (0.37) TRPM8AXLMAPTKDM4ESMN1; SMN2
SCHEMBL28825229 0.74 TRPM8 (0.40) TRPM8AXLMAPTKDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4642782-A2 ALPHA-V-BETA-8 INTEGRIN INHIBITORS AND USES THEREOF Pliant Therapeutics, Inc. (US) 2025-11-05 EP disclosed
US-12435078-B2 Pyridazinones and methods of use thereof GFB (ABC), LLC (US) 2025-10-07 US disclosed
EP-4616913-A2 GCN2 INHIBITORS AND USES THEREOF Merck Patent GmbH (DE) 2025-09-17 EP disclosed
EP-3746075-B1 GCN2 INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2025-09-03 EP disclosed
US-20250257076-A1 SUBSTITUTED PYRROLIDINE-2-CARBOXYLIC ACID DERIVATIVES AS cGAS INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2025-08-14 US disclosed
US-20250195480-A1 MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS Fulcrum Therapeutics, Inc. 2025-06-19 US disclosed
WO-2025092989-A1 SUBSTITUTED QUINAZOLINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMBINATION THEREOF, AND USE THEREOF 泰州红云制药有限公司 2025-05-08 WO disclosed
WO-2025072539-A1 AMINO ACID COMPOUNDS WITH NITROGEN LINKERS AND USES THEREOF PLIANT THERAPEUTICS, INC. (US) 2025-04-03 WO disclosed
CN-118852154-A Carboxamide substituted hetero tricyclic derivative, preparation method and application thereof 深圳微芯生物科技股份有限公司 2024-10-29 CN disclosed
WO-2024217500-A1 ISOQUINOLINE COMPOUND, AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF 上海赛默罗生物科技有限公司 2024-10-24 WO disclosed
CN-107108637-A Triazolopyrimidine compound and application thereof 诺华股份有限公司 2017-08-29 CN disclosed
US-9580437-B2 Triazolopyrimidine compounds and uses thereof NOVARTIS AG (CH) 2017-02-28 US disclosed
US-9580437-B2 Triazolopyrimidine compounds and uses thereof NOVARTIS AG (CH) 2017-02-28 US disclosed
US-9580437-B2 Triazolopyrimidine compounds and uses thereof NOVARTIS AG (CH) 2017-02-28 US disclosed
WO-2016103155-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF NOVARTIS AG (CH) 2016-06-30 WO disclosed
US-20160176882-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF NOVARTIS AG (CH) 2016-06-23 US disclosed
US-20160176882-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF NOVARTIS AG (CH) 2016-06-23 US disclosed
US-20160176882-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF NOVARTIS AG (CH) 2016-06-23 US disclosed
WO-2012086735-A1 CONDENSED HETEROCYCLIC COMPOUND 大正製薬株式会社 (JP) 2012-06-28 WO disclosed
CN-102459186-A Anthelmintic agents and uses thereof ANTHELMINTIC AGENTS AND THEIR USE 2012-05-16 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250195480-A1 MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS EED, EZH2, BMI1 TRPM8 3913/4885AXL 2526/4885MAPT 454/4885
US-12435078-B2 Pyridazinones and methods of use thereof PDXK, ATP6V1B1, REN TRPM8 1420/4885AXL 1512/4885MAPT 26/4885
US-20250257076-A1 SUBSTITUTED PYRROLIDINE-2-CARBOXYLIC ACID DERIVATIVES AS cGAS INHIBITORS CGAS, SSB, FPGS TRPM8 3187/4885AXL 4169/4885MAPT 3221/4885
US-20160176882-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF EZH2, DOT1L, EED TRPM8 4283/4885AXL 4251/4885MAPT 1539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.